Naslov
Identification of recent tuberculosis exposure using QuantiFERON-TB gold plus, a multicenter study

Autori
Pérez-Recio, Sandra ; Pallarès, Natàlia ; Grijota- Camino, Maria D. ; Sánchez-Montalvá, Adrián ; Barcia, Laura ; Campos-Gutiérrez, Silvia ; Pomar, Virginia ; Rabuñal-Rey, Ramón ; Balcells, María Elvira ; Gazel, Deniz ; Montiel, Natalia ; Vicente, Diego ; Goić-Barišić, Ivana ; Schön, Thomas ; Paues, Jakob ; Mareković, Ivana ; Cacho- Calvo, Juana ; Barac, Aleksandra ; Goletti, Delia ; García-Gasalla, Mercedes ; Barcala, José María ; Tórtola, María Teresa ; Anibarro, Luis ; Suárez- Toste, Isabel ; Moga, Esther ; Gude-Gonzalez, María J. ; Naves, Rodrigo ; Karslıgil, Tekin ; Martin-Peñaranda, Tania ; Stevanovic, Goran ; Trigo, Matilde ; Rubio, Verónica ; Karaoğlan, İlkay ; Bayram, Nazan ; Alcaide, Fernando ; Tebé, Cristian ; Santin, Miguel

Kolaboracija
ESCMID Study Group for Mycobacterial Infections (ESGMYC) ; Mycobacteria Study Group (GEIM) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)

Izvornik
Microbiology Spectrum (2165-0497) 9 (2021), 3; E00972-21, 10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
QuantiFERON-TB gold plus ; diagnosis ; latent tuberculosis infection ; tuberculosis-specific CD8 T cells

Sažetak
ABSTRACT We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune- mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB22TB1 value .0.6 IU
ml21 was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2.TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB22TB1 result of .0.6 IU
ml21 and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 15.4%, and 17.7% with close, frequent, and sporadic contact had a TB2.TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB22TB1 difference of .0.6 IU
ml21 was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA